396131-74-1

Basic information

• Product Name: 2-oxo-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide
• Synonyms: 2-oxo-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide
• CAS NO: 396131-74-1
• Molecular Weight: 449.472
• Mol File: 396131-74-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-oxo-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-oxo-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide(396131-74-1)
• EPA Substance Registry System: 2-oxo-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide(396131-74-1)

Safety Data

• Hazardous Substances Data: 396131-74-1(Hazardous Substances Data)

Upstream product

• 918-05-8 N,N-dimethylmethanesulfonamide 
• 361547-22-0 methyl (4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)acetate 
• 828-27-3 4-Trifluoromethoxyphenol 
• 350-46-9 4-Fluoronitrobenzene 
• 220616-47-7 4-(4'-trifluoromethoxyphenoxy)-benzenethiol 
• 58119-51-0 4-[4-(trifluoromethoxy)phenoxy]aniline 
• 74030-44-7 1-nitro-4-(4-(trifluoromethoxy)phenoxy)benzene 
• 361547-21-9 dithiocarbonic acid O-ethyl ester S-(4-(4-trifluoromethoxyphenoxy)phenyl) ester 

Downstream Products

• 396131-78-5 2-hydroxy-3-(4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)propane-1-sulfonic acid dimethyl amide 

Relevant articles and documents

Phenoxyphenyl sulfone N-formylhydroxylamines (Retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors

A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1′ substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a.highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.